Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hippuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | PTPRC | P08575 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hippuric Acid SCHEMBL7486 | 1.00 | GAA (0.68) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| SCHEMBL22030672 | 1.00 | GAA (0.68) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL3448563 | 0.98 | MAPT (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL15416338 | 0.98 | MAPT (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL11656206 | 0.98 | MAPT (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL11709120 | 0.98 | MAPT (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL8165809 | 0.98 | MAPT (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL21569381 | 0.98 | MAPT (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL657588 | 0.98 | KDM4E (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 | |
| Hippuric Acid SCHEMBL7398337 | 0.98 | MAPT (0.66) | GAAMAPTKDM4EHIF1ASLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230209-B3 | STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | UCB PHARMA GMBH (DE) | 2011-10-05 | — | — | EP | claimed |
| JP-2011524897-A | — | — | 2011-09-08 | — | — | JP | claimed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | claimed |
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| WO-2011012897-A1 | NEW COMBINATIONS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | claimed |
| US-20260053802-A1 | TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077 | GENENTECH, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-114008050-B | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119192134-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119192133-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119183377-A | Methods and compositions comprising an SHP2 inhibitor and a PD-L1 binding antagonist | 基因泰克公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-7919117-B2 | Drug delivery of fesoterodine (fumarate) through the skin in a dosage ofo.r-20 mg per day and is provided in a polymer matrix for uniform release;contact adhesives; sel-adhesives; impermeable backing; flatness; geratrics;drug delivery; side effect reduction | UCB PHARMA GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20110053914-A1 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2011023392-A1 | PHARMACEUTICAL COMBINATION COMPRISING 6-DIMETHYLAMINOMETHYL-1-(3-METHOXY-PHENYL)-CYCLOHEXANE-1,3-DIOL OR 6-DIMETHYLAMINOMETHYL-1-(3-HYDROXY-PHENYL)-CYCLOHEXANE-1,3-DIOL AND AN ANTIEPILEPTIC | Grünenthal GmbH (DE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011012897-A1 | NEW COMBINATIONS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| US-20090274761-A1 | TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN | SCHWARZ PHARMA AG (DE) | 2009-11-05 | — | — | US | disclosed |
| WO-2007038524-A2 | COCRYSTALLIZATION METHODS | SSCI, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-5756650-A | COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053802-A1 | TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077 | KRAS, NRAS, ASNS | GAA 2778/4885MAPT 4782/4885KDM4E 1447/4885 |
| US-20090274761-A1 | TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN | PLOD3, TH, CYP1A1 | GAA 4766/4885MAPT 4508/4885KDM4E 2619/4885 |
| US-20110053914-A1 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic | CACNA1A, GAP43, CACNG6 | GAA 634/4885MAPT 1581/4885KDM4E 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.